DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

Information source: Astellas Pharma Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pharmacokinetics of Isavuconazole; Healthy Subjects

Intervention: Isavuconazole (Drug); Esomeprazole (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Astellas Pharma Global Development, Inc.

Official(s) and/or principal investigator(s):
Senior Medical Director, Study Director, Affiliation: Astellas Pharma Global Development, Inc.

Summary

The purpose of this study is to assess the effect of multiple doses of esomeprazole on the pharmacokinetics of isavuconazole. In addition, safety and tolerability of isavuconazole alone and in combination with esomeprazole will be assessed

Clinical Details

Official title: A Phase 1 Randomized Open Label, Parallel Group Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

Pharmacokinetics of plasma isavuconazole concentration: Area under the concentration-time curve during the time interval between consecutive dosing (AUCtau)

Pharmacokinetics of plasma isavuconazole concentration: Maximum concentration (Cmax)

Pharmacokinetics of plasma isavuconazole concentration: Time after dosing when Cmax occurs (tmax)

Safety assessed through adverse events

Safety assessed through clinical laboratory evaluations

Safety assessed by 12-lead electrocardiograms (ECGs)

Safety assessed through vital signs

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- The subject has a body weight of at least 50 kg and a body mass index of 18. 5 to 32

kg/m2, inclusive

- The subject's 12-lead electrocardiogram (ECG) is normal

- The subject's clinical laboratory test results are within normal limits

Exclusion Criteria:

- The subject has any history or evidence of any clinically significant cardiovascular,

gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy

- The subject has a history of bowel obstruction, swallowing disorder, severe

gastro-intestinal disorders, major gastrointestinal surgery, gastric/duodenal ulcers or any other condition that may interfere with study drug absorption

- Female subject has been pregnant within 6 months before screening or breast feeding

within 3 months before screening

- The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac

arrhythmia or torsade de pointes, structural heart disease, or family history of either Short or Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes). QT is the time between the start of the Q wave and the end of the T wave in the heart's electrical system

- The subject has/had febrile illness or symptomatic, viral, bacterial (including upper

respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic admission

- The subject has received a vaccination within the last 30 days prior to study drug

administration

- The subject has a positive serology test for Hepatitis B surface antigen (HBsAg),

Hepatitis A Immunoglobulin M antibody (anti HAV (IgM)), Hepatitis C antibody (anti-HCV), or human immunodeficiency virus (anti-HIV 1+2)

- The subject has a known or suspected allergy to any of the components of the trial

products or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods, or a history of severe anaphylactic reactions

- The subject has used tobacco or nicotine containing products in the last 6 months

- The subject has had treatment with any prescribed or non-prescribed drugs (including

vitamins, natural and herbal remedies, e. g. St. John's wort) in the 2 weeks prior with the exception of hormonal methods of contraception, hormone replacement therapy, or occasional use of acetaminophen up to 2 g/day

- The subject has participated in any interventional clinical study or has received any

investigational drugs within past 30 days or 5 half-lives, whichever is longer

- The subject has had any significant blood loss, donated one unit (450 mL) of blood or

more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission

- The subject anticipates an inability to abstain from alcohol or caffeine use for 48

hours prior and throughout the duration of the study; or from grapefruit, grapefruit juice, star fruit, or Seville oranges or any products containing these items from 72 hours prior and throughout the duration of the study

- The subject has history of consuming more than 14 units of alcoholic beverages per

week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates)

- The subject has taken part in strenuous exercise within 3 days before Day 1

Locations and Contacts

Parexel Early Phase Clinical Unit, Baltimore, Maryland 21225, United States
Additional Information

Starting date: January 2014
Last updated: April 30, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017